Table 2. IC50 concentrations expressed in μM for the in vitro cell growth inhibition induced by exposure to fascaplysin (1), CA198 (3), CA199 (4), CA211 (5) and BPT (6) for 48 h and measured by MTT assay.
| Cell lines | Fascaplysin (1) | CA198 (3) | CA199 (4) | CA211 (5) | BPT (6) |
|---|---|---|---|---|---|
| LS174T (colorectal carcinoma; p53+, pRb+) | 0.88+0.04 | 33+2.5 | 7.1+1.3 | 29+2 | 0.85+0.07 |
| PC-3 (prostate; p53 null, pRb+) | 0.92+0.06 | 42+3 | 13.1+1.8 | 32+1.5 | 0.74+0.09 |
| MiaPaCa (pancreatic; p53His273mut, pRb+) | 0.88+0.2 | 43+5 | 8.5+ 1.3 | 29+4.5 | 0.8+0.1 |
| A549 (NSCLC; p53+, pRb+) | 0.69+0.03 | 46+4 | 8.0+2 | 31+3.5 | 0.92+0.08 |
| Calu-1 (NSCLC; p53 null, pRb+) | 1.3+0.1 | 92+4.5 | 47+3.5 | 54+4 | 2.8+0.4 |
| NCI-H460 (NSCLC; p53+, pRb+) | ND | 29+3.5 | 6.2+0.7 | 22+2 | 0.6+0.06 |
| NCI-H1299 (NSCLC; p53 null, pRb+) | ND | 35+2 | 4.5+0.5 | 30+1 | 0.9+0.045 |
| NCI-H358 (NSCLC; p53 null, pRb null) | ND | 28+4 | 3.5+0.8 | 25+1.5 | 0.68+0.07 |
| BNL CL2 (mouse normal hepatic cells) | ND | 37+1.5 | 6.5+0.7 | 27+2.5 | 0.72+0.1 |
| BNL SV A.8 (mouse hepatic; SV40-mediated transformed cells) | ND | 40+3.5 | 8.2+1 | 35+3 | 0.75+0.08 |
All results represent means and S.D. from at least three independent experiments